aviscera bioscience  
AVISCERA BIOSCIENCE  
line decor
  HOME  ::  
line decor
   
 
CTRP9/C1QTNF9 ELISA, Recombinant & Antibodies
  • C1q/TNF-related protein 9
  • C1q-like 9
Dr. Takahiro Kambara had used CTRP9 (Human) Full Length (Code: 00081-04-100) and Anti CTRP9 (Mouse) IgG (Code: A00081-03-100) from Aviscera Bioscience (AVISCERA BIOSCIENCE ,INC FORMALLY KNOWN AS ADIPO BIOSCIENCE,INC) on following research paper.

CTRP9 Protein Protects against Myocardial Injury following Ischemia-Reperfusion through AMP-activated Protein Kinase (AMPK)-dependent Mechanism

Ischemic heart disease is the major cause of death in Western countries. CTRP9 (C1q/TNF-relatedprotein 9) is a fat-derived plasma protein that has salutary effects on glucose metabolism and vascular function. However, the functional role of CTRP9 in ischemic heart disease has not been clarified. Here, we examined the regulation of CTRP9 in response to acute cardiac injury and investigated whether CTRP9 modulates cardiac damage after ischemia and reperfusion. Myocardial ischemia-reperfusion injury resulted in reduced plasma CTRP9 levels and increased plasma free fatty acid levels, which were accompanied by a decrease in CTRP9 expression and an increase in NADPH oxidase component expression in fat tissue. Treatment of cultured adipocytes with palmitic acid or hydrogen peroxide reduced CTRP9 expression. Systemic administration of CTRP9 to wild-type mice, before the induction of ischemia or at the time of reperfusion, led to a reduction in myocardial infarct size following ischemia-reperfusion. Administration of CTRP9 also attenuated myocyte apoptosis in ischemic heart, which was accompanied by increased phosphorylation of AMP-activated protein kinase (AMPK). Treatment of cardiac myocytes with CTRP9 protein reduced apoptosis in response to hypoxia/reoxygenation and stimulated AMPK phosphorylation. Blockade of AMPK activity reversed the suppressive actions of CTRP9 on cardiomyocyte apoptosis. Knockdown of adiponectin receptor 1 diminished CTRP9-induced increases in AMPK phosphorylation and survival of cardiac myocytes. Our data suggest that CTRP9 protects against acute cardiac injury following ischemia-reperfusion via an AMPK-dependent mechanism.
Takahiro Kambara et al. J Biol Chem. 2012 June 1; 287(23): 18965–18973. Published online 2012 April 18. doi:  10.1074/jbc.M112.357939
 
Dr. Noriyuki Ouchi and Dr. Rei Shibata had used CTRP9 (Human) Full Length (Code: 00081-04-100) and Anti CTRP9 (Mouse) IgG (Code: A00081-03-100) from Aviscera Bioscience (AVISCERA BIOSCIENCE ,INC FORMALLY KNOWN AS ADIPO BIOSCIENCE,INC) on following research paper.
Adipose-derived factor CTRP9 attenuates vascular smooth muscle cell proliferation and neointimal formation
Obesity is closely associated with the progression of vascular disorders, including atherosclerosis and postangioplasty restenosis. C1q/TNF-related protein (CTRP) 9 is an adipocytokine that is down-regulated in obese mice. Here we investigated whether CTRP9 modulates neointimal hyperplasia and vascular smooth muscle cell (VSMC) proliferation in vivo and in vitro. Left femoral arteries of wild-type (WT) mice were injured by a steel wire. An adenoviral vector expressing CTRP9 (Ad-CTRP9) or β-galactosidase as a control was intravenously injected into WT mice 3 d before vascular injury. Delivery of Ad-CTRP9 significantly attenuated the neointimal thickening and the number of bromodeoxyuridine-positive proliferating cells in the injured arteries compared with that of control. Treatment of VSMCs with CTRP9 protein attenuated the proliferative and chemotactic activities induced by growth factors including platelet-derived growth factor (PDGF)-BB, and suppressed PDGF-BB-stimulated phosphorylation of ERK. CTRP9 treatment dose-dependently increased cAMP levels in VSMCs. Blockade of cAMP-PKA pathway reversed the inhibitory effect of CTRP9 on DNA synthesis and ERK phosphorylation in response to PDGF-BB. The present data indicate that CTRP9 functions to attenuate neointimal formation following vascular injury through its ability to inhibit VSMC growth via cAMP-dependent mechanism, suggesting that the therapeutic approaches to enhance CTRP9 production could be valuable for prevention of vascular restenosis after angioplasty.
Yusuke Uemura , et al. The FASEB Journalvol. 27 no. 1 25-33/ Published online before printSeptember 12, 2012, doi:10.1096/fj.12-213744
human ctrp9 elisa kit sk00081-02 Human CTRP9 ELISA KIt
Code No.: SK00081-02
Size: 96 T
Price: $450.00 USD 
Standard range: 3.9-1000 ng/ml
Sensitivity: 0.15 ng/ml
Sample Type: serum
Sample require: 100 uL per well
Intra-CV:4-6%
Inter-CV: 8-10% 
Protocol: PDF
Mouse CTRP9 ELISA KIt
Code No.: SK00081-08
Size: 96 T
Price: $450.00 USD 
Standard range: 78-5000 ng/ml
Sensitivity:15 ng/ml
Sample Type: serum
Sample require: 100 uL per well
Intra-CV:4-6%
Inter-CV: 8-10% 
Protocol: PDF
CTRP9 Full Length (Human) Recombinant
Code No.: 00081-04-100
Size: 100 ug
Price: $360.00 USD
Protein ID: NP_848635
Gene ID:NM_178540
MW:34.56 KD
Tag: His Tag on N-Terminus
Expressed: E. Coli
Purity: 90%
Data Sheet: PDF
CTRP9 Globular Form (Human) Recombinant
Code No.: 00081-01-100
Size: 100 ug
Price: $295.00 USD
Protein ID: NP_848635
Gene ID:NM_178540
MW:16 KD
Tag: His Tag on N-Terminus
Expressed: E. Coli
Purity: 95%
Data Sheet: PDF
CTRP9 Globular Form (Mouse) Recombinant
Code No.: 00081-03-100
Size: 100 ug
Price: $295.00 USD
Protein ID: AAY21933
Gene ID:DQ002401
MW:16 KD
Tag: His Tag on N-Terminus
Expressed: E. Coli
Purity: 95%
Data Sheet: PDF
Anti CTRP9 (Human) IgG
Code No.: A00081-01-100
Size: 100 ug
Price: $260.00 USD
Host: Rabbit
Antigen: human CTRP9
Ab Type: Polyclonal IgG
Purification: Protein A
Applications: E, IHC, WB
Working Dilution: IHC 2-4 ug/ml
Data Sheet: PDF

 

Name
Code No.
Size
Price
     
CTRP9 (Human) ELISA Kit
96 T
450.00
CTRP9 (Mouse, Rat) ELISA Kit
96 T
450.00
     
Anti-CTRP9 (H) IgG
100 ug
260.00
Anti-CTRP9 (H) IgG, Biontinylated
A00081-01-100B
100 ug
360.00
Anti-CTRP9 (H) IgG, Biontinylated (Detection)
50 ug
450.00
Anti-CTRP9 (H) IgG, FITC conjugated
A00081-01-100F
100 ug
360.00
Anti-CTRP9 (H) IgG, CY3 conjugated
A00081-01-100C3
100 ug
495.00
Anti-CTRP9 (M) IgG
100 ug
460.00
Anti-CTRP9 (M) IgG, Biontinylated
A00081-03-100B
100 ug
620.00
Anti-CTRP9 (M) IgG, FITC conjugated
A00081-03-100F
100 ug
590.00
Anti-CTRP9 (M) IgG, CY3 conjugated
A00081-03-100C3
100 ug
695.00
 
 
CTRP9 (Human), globular form
50 ug
180.00
CTRP9 (Human), globular form rec.
100 ug
295.00
CTRP9 (Human), globular form
1 mg
inquire
CTRP9 (Human), globular form Biotinylated
00081-01-B
50 ug
360.00
CTRP9 (Human), globular form CY3 conjugated
00081-01-C5
50 ug
495.00
CTRP9 (Human), globular form CY5 conjugated
00081-01-C3
50 ug
495.00
CTRP9 (Human), globular form FITC conjugated
00081-01-F
50 ug
450.00
CTRP9 (Human) full length
100 ug
295.00
CTRP9 (Mouse), globular form
50 ug
180.00
CTRP9 (Mouse), globular form rec.
100 ug
295.00
CTRP9 (Mouse), globular form
1 mg
inquire
Anti CTRP9 (Human) IgG
100 ug
460.00
Anti CTRP9 (Human) IgG
50 ug
590.00